Importantly, GFAP has been recently added to the NIA‐AA Revised Clinical Criteria as a biomarker of neuroinflammation in AD, paving the way for the future progress in the scenario of blood‐based biomarkers of inflammation. This evidence concerns the gene GFAP and Alzheimer disease.